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Background: Despite aggressive multimodality treatment, 5-year
survival of stage III non-small cell lung cancer (NSCLC) remains
30%. To detect relapse, progression, or development of a second
primary cancer early, many clinicians perform follow-up scans. To
assess the impact of routine scanning, we compared clinical trial
patients who had study-mandated scans with those treated off-study
who had less intensive radiologic follow-up.
Methods: The hospital cancer registry and trials databases were
searched for patients with locally advanced NSCLC who had un-
dergone multimodality treatment with curative intent. Baseline de-
mographics were collected as well as frequency and results of
clinical and radiologic follow-up.
Results: Forty trial patients and 35 nontrial control patients were
identified. Trial patients underwent significantly more imaging,
particularly in the first 2 years (2.9 versus 2.0 body scans per year,
p  0.0016; 1.1 versus 0.4 brain scans per year, p  0.001) but did
not have more frequent follow-up visits. Forty-five cancers were
detected (41 relapses, four metachronous primary tumors) in 44
(59%) patients. Of these, 28 (64%) sought medical attention that led
to detection before a scheduled appointment or procedure. There
was no significant difference in time to relapse or second primary in
trial and nontrial patients (p  0.80). Twenty-three patients had
localized relapse, but only 15 could be treated with curative intent.
Despite the trial group demonstrating a higher number of asymp-
tomatic cancers and being offered potentially curative therapy more
frequently, there was no significant difference in survival between
trial and nontrial patients.
Conclusion: In patients with locally advanced NSCLC, frequent
cross-sectional imaging does not alter survival after combined mo-
dality therapy.
Key Words: Non-small cell lung cancer, Diagnostic imaging, Com-
puted tomography, Follow-up.
(J Thorac Oncol. 2007;2: 273–281)
Lung cancer accounts for the largest number of cancer-related deaths in North America.1 For patients with early-
stage non-small cell lung cancer (NSCLC), surgery is the
treatment of choice, followed by adjuvant chemotherapy.2–4
Approximately one third of NSCLC patients present with
locally advanced tumors (stages IIIA and IIIB), and for some
of these patients, a combined modality treatment approach
undertaken with potentially curative intent may be appropri-
ate.5 There is a lack of evidence in the published literature
regarding optimal follow-up of NSCLC treated with curative
intent.6 In patients with locally advanced lung cancer, argu-
ments have been made for intensive follow-up as relapse rates
are high, but little is known about the effectiveness of
follow-up regimens, and there is a lack of evidence to suggest
that earlier treatment of recurrence leads to better outcomes.
Edelman et al.7 described the following principles for the use
of diagnostic tests in the evaluation of patients after poten-
tially curative cancer therapy: (1) the interval between exam-
inations and the duration of testing should be consistent with
the maximal risk of recurrence and the natural history of the
tumor; (2) tests should be directed at the most likely sites of
recurrence and should have high positive and negative pre-
dictive values; (3) therapy should be available that will result
in cure, significant prolongation of life, or palliation of
symptoms; (4) initiation of earlier therapy should improve
outcome; (5) increased risk of second malignancies should
guide tests. Potential negative aspects of routine tests include
increased patient anxiety, increased cost, investigation of
incidental findings at routine scanning, and unnecessary in-
tervention.
In our institution, when patients attend for routine
follow-up, history and physical examination, a chest radio-
graph (CXR), and biochemical blood tests are performed
routinely, approximately every 3 months for 2–3 years and
then every 6 months to 5 years (Table 1). Further diagnostic
tests such as computed tomography (CT) or magnetic reso-
nance imaging (MRI) are performed only when there is a
clinical suspicion of relapse. However, for patients who are
enrolled in clinical trials, routine cross-sectional imaging
often forms part of the study follow-up protocol. Our insti-
tution participated in two North American Intergroup trials of
combined modality therapy for stage III NSCLC,8,9 and
following closure of these studies, patients were treated in an
identical fashion using the same chemotherapy, radiotherapy,
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and surgical protocols. By comparing patients treated on
study who had study-mandated follow-up scans with those
treated off-study with less intensive radiologic follow-up, we
sought to answer the following questions: (1) How, when,
and where is relapse detected? (2) Does intensive radiologic
follow-up detect relapse at an earlier stage, and, if so, can
curative treatment be offered and outcomes improved? (3)
Does an abnormality detected on a routine scan precipitate a
change in patient management?
PATIENTS AND METHODS
Patient Identification
Trial patients
Our hospital cancer trials database was searched retro-
spectively for all patients enrolled in the Southwest Oncology
Group 9416 (Intergroup [INT] 0160) and INT 0139. INT
0160 was limited to patients with T3 or T4 superior sulcus
tumors with N0 or N1 disease (node negative at mediastinos-
copy). INT 0139 patients all had mediastinoscopy-proven N2
disease. In both studies, patients underwent neoadjuvant che-
moradiotherapy (CT/RT) consisting of two cycles of etopo-
side and cisplatin and radiotherapy (45 Gy in 25 fractions).
Patients in INT0160 then proceeded to surgical resection.
Patients in INT 0139 were randomized into surgical and
nonsurgical arms; the nonsurgical patients received 2 more
weeks of radiotherapy to a total dose of 63 Gy. In both trials,
two additional cycles of etoposide and cisplatin were admin-
istered postoperatively or post-radiation.
Nontrial patients
Approval for this study was granted by the ethics
committee of the University Health Network. The hospital
cancer registry was searched retrospectively for all consecu-
tive patients who presented with the same stage disease and
were offered similar definitive treatment in the posttrial era.
Any patients who progressed on treatment or who did
not undergo follow-up were excluded. For all patients, the
following data were collected: baseline demographics at pre-
sentation including age, sex, tumor cell type and stage at
presentation, treatment, response, pathologic stage at resec-
tion (if surgery was performed), date and frequency of clin-
ical and radiologic follow-up, and whether this was “sched-
uled” (as part of a clinical trial protocol or routine clinical
follow-up in nontrial patients) or “unscheduled” (symptom
driven).
Follow-up
Initial follow-up for all patients was defined as the first
encounter occurring after completion of all treatment. Table 1
details the follow-up regimens for the various patient groups.
In all patients, biochemistry consisted of electrolytes, creati-
nine, aspartate transaminase, alanine transaminase, alkaline
phosphatase, calcium, and lactate dehydrogenase. The non-
trial patients were followed regularly with history, physical
examination, CXR, and routine biochemistry. Further radio-
logic examinations were only arranged when there was a
clinical suspicion of relapse. All patients had at least 2 years
of follow-up.
Relapses
Relapse was defined as recurrence after response to
primary therapy or the development of a metachronous tu-
mor. Relapses were recorded as detected during a scheduled
or unscheduled radiologic procedure and also according to
presence of symptoms. Methods of detection of relapse were
recorded, including physical examination and CXR; cross-
sectional imaging of the chest, body, or brain; and other
investigations. The site of relapse was described as thoracic
or extrathoracic. Local thoracic recurrence was defined as
recurrent tumor at the previous primary tumor site or nodal
disease that might be amenable to surgery or radical radio-
therapy. Case notes and radiology records were reviewed to
determine whether clinical or radiologic findings suggestive
of relapse altered management.
Survival and Statistical Analyses
The study was a two-cohort design. The number of
hospital visits and diagnostic tests were compared between
the trial and nontrial groups, assuming Poisson distribution.
TABLE 1. Follow-up Regimens for Intergroup Trial and Nontrial Patients
Trial Tests at Initial Follow-up
Definition of
Subsequent Follow-up Tests at Subsequent Follow-up
INT 0160 Biochemistry, CXR, CT of chest and
upper abdomen, CT or MRI of
brain. Bone scan only if indicated
by symptoms or chemistry
Every 3 mo for 2 yr,
then every 6 mo
thereafter
Biochemistry, CXR at each visit. CT of chest, upper
abdomen and CT or MRI of brain every 6 mo for 3
yr, then as required. Bone scan only if indicated by
symptoms or chemistry
INT 0139 Biochemistry, CXR, CT of chest and
upper abdomen, CT or MRI of
brain and bone scan only if
indicated by symptoms or
chemistry
Every 2 mo for 1 yr,
then every 3 mo for 2
yr, then every 6 mo
thereafter
Biochemistry, CXR at each visit. CT of chest and
upper abdomen and CT/MRI of brain at 12, 18, 24
mo and yearly thereafter. Bone scan only if
indicated by symptoms or chemistry
Nontrial patients Biochemistry, CXR only. Further
tests if clinically indicated
Regular clinical review
approximately every 3
mo for 2–3 yr and
every 6 mo for 2–3 yr
Biochemistry, CXR only. Further tests if clinically
indicated
CXR, chest radiograph; CT, computed tomography; MRI, magnetic resonance imaging.
Benamore et al. Journal of Thoracic Oncology • Volume 2, Number 4, April 2007
Copyright © 2007 by the International Association for the Study of Lung Cancer274
A relapse was defined as either recurrence after response to
primary therapy or a second malignancy. The proportions of
imaging that detected a relapse were compared between the
trial and nontrial groups using a generalized linear model
with a logistic link. The proportions of relapses at each point
in time were calculated using the cumulative incidence func-
tion. Because some patients died before experiencing a re-
lapse, the comparison between the two groups was performed
using Gray’s test. Survival measured from the end of the
treatment was calculated using the Kaplan-Meier approach,
and the groups were compared using the log-rank test.
RESULTS
Patient Characteristics
Fifty-six patients enrolled in INT 0160 and INT 0139
initially were identified. Sixteen were excluded for the fol-
lowing reasons: progressive disease during treatment (nine
patients), death before follow-up (five patients), lost to fol-
low-up (one patient), cell type not NSCLC (one patient).
Therefore, a total of 40 trial patients were enrolled (11 with
superior sulcus tumors and 29 N2 nodal disease). After
review of the hospital cancer registry, 69 potential nontrial
patients were identified. Thirty-four patients were excluded
for the following reasons: incorrect tumor stage after full
staging investigations (14 patients), incomparable treatment
(five patients), disease progression during treatment (four
patients), death before follow-up (two patients), lost to fol-
low-up (eight patients), cell type not NSCLC (one patient).
Therefore, a total of 35 nontrial patients were enrolled (11
with superior sulcus tumors and 24 with N2 nodal disease).
Table 2 summarizes the baseline characteristics of the two
patient groups.
Follow-up
The median duration of follow-up was 77 months
(range, 50–117) for trial patients and 44 months (range,
23–76) for nontrial patients (Table 2). This difference is due
to the adoption of the trial treatment into standard practice
after the trials closed. For both trial and nontrial patients, the
frequency of follow-up, lab tests, and radiologic examina-
tions is greater than that stated in the methods, as this also
includes symptomatic presentations between scheduled visits.
As shown in Table 3, there was no statistical difference in the
frequency of follow-up visits between the trial and nontrial
groups. However, trial patients underwent significantly more
imaging, particularly in the first 2 years (2.9 versus 2.0 body
scans per year, p  0.0016; 1.1 versus 0.4 brain scans per
year, p  0.0001). Significance was not changed when
controlling for age, gender, histology, and type of trial.
Relapses and Survival
Up to the time of detection of first relapse, a total of 388
and 166 cross-sectional imaging studies were performed in
the trial and nontrial patients, respectively (p  0.09) (Table
4, Figure 1). In total, 45 relapses were detected (41 recur-
rences and four metachronous primary tumors) in 44 (61% at
5 years) patients. As shown in Figure 1, 24 recurrences and
three metachronous primary tumors were detected in 26 trial
TABLE 3. Comparison of Frequency of Follow-up Visits,
Blood Tests, and Radiologic Examinations per Patient
Trial Nontrial p
0–2 yr of follow-up (n  75)
Average no. of visits per year 4.6 4.6 0.91
Average no. of CXRs per year 4.4 3.9 0.14
Average no. of lab tests per year 3.6 2.4 0.013
Average no. of brain scans per year 1.1 0.4 0.0001
Average no. of body CT scans per year* 2.9 2.0 0.0016
2–5 yr of follow-up (n  48)
Average no. of visits per year 3.0 3.2 0.54
Average no. of CXRs per year 2.6 2.6 0.83
Average no. of lab tests per year 2.3 1.7 0.27
Average no. of brain scans per year 0.8 0.5 0.04
Average no. of body CT scans per year* 2.0 1.5 0.11
5 yr of follow-up (n  18)
Average no. of visits per year 2.1 2.4 0.66
Average no. of CXRs per year 2.0 1.5 0.56
Average no. of lab tests per year 1.3 1.8 0.56
Average no. of brain scans per year 0.04 0.3 0.17
Average no. of body CT scans per year* 0.8 1.2 0.41
*Body scans usually comprised computed tomography of the chest, upper abdomen,
and occasionally the pelvis. For the purposes of this analysis, they are counted as
separate examinations to reflect the practice of separate billing and reporting. CXRs,
chest radiographs; CT, computed tomography.
TABLE 2. Clinical Characteristics
Trial
(n  40)
%
Nontrial
(n  35)
%
Total
(n  75)
% p
Median age, yr 60.5 60 60 0.83
Gender
Female 15 (37) 15 (43) 30
Male 25 (63) 20 (57) 45 0.64
Median duration of
follow-up, mo
Alive patients 77 44 58 0.0002
All patients 48 33 36
Stage*
IIB 7 (18) 6 (17) 13 0.63
IIIA 30 (75) 24 (69) 54
IIIB 3 (7) 5 (14) 8
Histology
Adenocarcinoma 16 (40) 16 (46) 33
Squamous carcinoma 15 (37) 13 (37) 28 0.70
Large cell carcinoma 4 (10) 2 (6) 6
Adenosquamous carcinoma 1 (3) 1 (3) 2
Undifferentiated 4 (10) 3 (8) 7
Treatment
CT/RT and surgery 26 (65) 20 (57) 46
CT/RT alone 14 (35) 15 (43) 29
Postinduction CT 30 (75) 18 (51) 48
Boost CT/RT 4 (10) 2 (6) 6
Percentages are calculated for each of the trial and nontrial groups.
*Clinical stage before treatment.
CT, chemotherapy; RT, radiotherapy.
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patients (63% at 5 years) and 17 recurrences and one meta-
chronous tumor in 18 nontrial patients (60% at 5 years,
Figure 2). Twenty-eight of the 44 patients with relapse (64%)
sought medical attention that led to the detection of relapse
before a scheduled appointment or procedure (14 trial pa-
tients and 14 nontrial patients). In fact, trial patients were as
likely to have relapse detected with an unscheduled procedure
as with routine study protocol tests (14 versus 13 relapses).
A total of 454 biochemical investigations were per-
formed up to and including the time of relapse. Fifty-six
(12.3%) were abnormal, with no other evidence of relapse. In
contrast, in the 44 patients with confirmed relapse, biochem-
istry was normal in 39 (88.6%) and suspicious in five (11.4%)
at the time of relapse. There was no patient in whom abnor-
mal biochemistry was the sole presenting feature of relapse.
CT scans of the abdomen were usually confined to the upper
TABLE 4. Summary of Scans Performed and Scan Results up to and Including the Detection of First Relapse
Trial Patients Nontrial Patients
Relapses No. of Scans No. Showing Relapse % No. of Scans No. Showing Relapse % p
All cross-sectional imaging 388 35 11 166 25 18 0.092
Brain imaging 94 10 13 19 9 50 0.0062
Body imaging 294 25 10 147 16 12 0.46
FIGURE 1. Detection of relapses and metachro-
nous primary tumors for both the trial (T) and
nontrial (NT) patients. Scheduled procedures in-
clude physical examination and chest radiograph
(CXR), which detected the asymptomatic relapses
in the nontrial group. Other radiologic investiga-
tions included bone scan and computed tomogra-
phy (CT) of the neck.
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abdomen to cover the liver and adrenal glands. However, 39
pelvic CT scans were also performed in some patients. Only
one demonstrated pelvic lymphadenopathy in a patient with
widespread metastases that were detected on the upper ab-
dominal scan as well.
As can be seen in Figure 2, there was no significant
difference in the time to disease relapse or second primary
tumor in trial and nontrial patients (p  0.80). Thoracic
recurrence was infrequent, occurring in only 19% of patients
with adenocarcinoma and 15% of patients with squamous
carcinoma (Figure 3A). In contrast, extrathoracic relapse
(Figure 3B) was significantly more frequent in patients with
adenocarcinoma (adenocarcinoma 51% versus squamous
17% at 5 years, p  0.003).
Treatment at the Time of Relapse or Second
Primary
There was no significant difference in management of
relapses detected by symptoms or routine scans. In the trial
group, there were three asymptomatic metachronous tumors,
all treated with curative intent. One lung cancer was detected
by routine CXR; the patient was treated surgically and is still
FIGURE 2. Comparison of time to development
of relapse or second primary tumor in trial and
nontrial patients.
FIGURE 3. Interval between end of treatment
and intrathoracic (A) and extrathoracic (B) relapse,
according to histology. AD, adenocarcinoma; SQ,
squamous carcinoma.
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alive 3 years later. Lung and esophageal cancers were de-
tected by routine CT scans, with the patients surviving 28 and
20 months, respectively, following treatment. One nontrial
patient, who initially underwent pneumonectomy, had a
metachronous symptomatic lung carcinoma that was treated
palliatively with chemoradiotherapy.
Isolated local thoracic recurrence was only detected in
six (14%) patients (Figure 1), of which only two trial patients
could be treated with curative intent. One asymptomatic
patient underwent a completion pneumonectomy, but died 4
months later from disseminated metastatic disease; the other
patient was symptomatic, underwent completion pneumonec-
tomy, and is still alive 2 years later. These numbers are too
small to permit further statistical analysis.
Thirteen patients developed isolated brain metastases.
Four of eight trial patients were asymptomatic, with solitary
brain metastases, and all underwent treatment with curative
intent. A further five symptomatic patients with solitary
metastases also underwent attempted curative therapy (three
trial and two nontrial patients). Median survivals were 24.8
and 21.9 months for brain metastases detected routinely and
symptomatically, respectively.
Overall, 23 patients had localized relapses (Figure 1),
but only 15 of these could be treated with curative intent (12
of 15 trial patients and three of eight nontrial patients).
Despite the trial group demonstrating a higher number of
asymptomatic relapses and being offered potentially curative
therapy more frequently, there was no significant difference
in the length of survival between trial and nontrial patients
(Figure 4).
Similarly, there was no difference in survival from the
time of relapse or second primary (p  0.13). Although
patients who were asymptomatic at the time relapse was
detected (by routine scanning) appeared to survive longer
than symptomatic patients, they were identified significantly
sooner after the end of treatment (p  0.037) in keeping with
lead time bias (Figure 5) and their overall survival from the
date of completion of therapy was not longer than that of
symptomatic patients.
DISCUSSION
Follow-up of patients with NSCLC is aimed at early
detection of relapse or metachronous primary tumors and
management of treatment-related complications. However,
the early detection of relapse or second primary cancer
should, in and of itself, not be a primary end point if
potentially curative therapy is not available. Thus, a more
rigorous end point for follow-up studies would be overall
survival. Most studies have concentrated on examining meth-
ods of follow-up in early-stage resected NSCLC,10 whereas
the issues surrounding locally advanced lung cancer are more
complex. Relapse rates are much higher in this group of
patients, although the pattern of relapse tends to be similar
with the majority of relapses being systemic and frequently
multiple. This suggests that for the majority of patients,
curative therapy at the time of relapse will not be an option.
Westeel et al.11 followed 192 patients intensively with
cross-sectional imaging following complete resection of
NSCLC. Median survival was 24 months from the date of
operation and 7 months from the date of relapse. They
showed no difference in disease-free interval between asymp-
tomatic and symptomatic patients, although they reported
significantly longer survival in patients who were asymptom-
atic at the time of recurrence. They concluded that intensive
follow-up with CT and bronchoscopy prolongs survival. Our
study does not support these findings and in fact suggests a
lead-time bias, with no significant difference in overall sur-
vival between intensive routine CT scanning and symptom-
driven investigation. However, all our patients had locally
advanced disease compared with only 36% of the patients of
Westeel et al., and our study population was small.
The results of our study are similar to those of Walsh et
al.,12 who assessed the development of relapse or second
primary tumor in 358 patients who had undergone surgical
resection for lung cancer. Of this group, 111 had locally
advanced disease and 55% of this subgroup relapsed. Nearly
half of the patients with a symptomatic relapse sought med-
ical attention before a scheduled appointment. They con-
cluded that regular monitoring does not appear to be cost-
effective and that patients whose relapse was detected
asymptomatically had no overall survival advantage but were
diagnosed earlier, suggesting lead-time bias. This finding is
confirmed by our data. Lamont et al.13 followed 124 patients
with resected lung cancer with annual CT scans of the chest
and concluded that second lung cancers may be amenable to
FIGURE 4. A comparison of survival for trial and
nontrial patients from the start of the follow-up
period at the completion of definitive treatment.
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surgery, but local recurrence has a poor prognosis, as con-
firmed by our study.
Although some patients may be reassured by intensive
follow-up, many experience significant anxiety. The impact
of awaiting test results or investigating false-positive findings
must be taken into account. Given that nearly two thirds of
patients developed symptoms between scheduled appoint-
ments and investigations, this suggests that the current fol-
low-up regimens are suboptimal. All our patients were fol-
lowed by their cancer specialists, the cost effectiveness of
which has been questioned.14,15 Moore et al.16 have suggested
that nurse practitioner follow-up results in fewer investiga-
tions yet similar survival and is preferred by many patients.
Our trial patients were followed with standard dose CT.
Low-dose CT (LDCT) has shown promise in the context of
screening for lung cancer,17 although it has a high false-
positive rate. LDCT has not been studied extensively as a
follow-up tool, although one small prospective study18
showed that regular LDCT of the thorax is effective in
detecting recurrence after attempted curative resection of
NSCLC. However, the impact of this on survival is unknown.
Our hospital currently is comparing LDCT with CXR
follow-up in a cohort of completely resected patients with
NSCLC.
In our study, 13 (29%) patients relapsed first in the
brain, and four of these patients were asymptomatic. Yokoi et
al.19 performed frequent follow-up CT brain examinations in
128 patients following surgical resection for lung cancer.
Seven of 11 relapses were asymptomatic (the majority being
in patients with stage IIIA disease). They noted a marked
difference in median survival in the asymptomatic group. We
observed no significant difference in survival between
asymptomatic and symptomatic relapses in the brain or in
other organs, but the numbers of patients are small and the
INT 0160 and INT 0139 follow-up regimens were less
intensive than those of Yokoi et al. Five of nine trial patients
presented with symptomatic brain metastases between sched-
uled scans. Carolan et al.20 found that in patients with ad-
vanced NSCLC, the brain was the first site of relapse in 18%,
but in patients younger than 60, the risk of relapse was 25%.
Our incidence of brain relapse in this study is at the higher
end of quoted figures, which may reflect the relatively young
study population, the advanced local stage of disease, and
also early detection of asymptomatic metastases. The high
rate of brain relapse in patients with stage III NSCLC has
prompted a prospective, randomized trial of prophylactic
cranial irradiation versus observation alone in this population.
The trial is open in Europe and North America and should be
supported vigorously. It is unknown what impact follow-up
with MRI scans of the brain may have on survival, as this is
now considered the accepted standard of diagnostic test.
It is well known that patients with previously treated
NSCLC are at an increased risk of developing second primary
tumors, most commonly in the aerodigestive tract and pub-
FIGURE 5. A comparison of interval between the
end of treatment and relapse (a) and survival
since relapse (b) in symptomatic and asymptom-
atic patients.
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lished data suggest less than 20% 5 year survival.21,22 Inten-
sive follow-up with CT may detect new lung cancers at a stage
when they are amenable to surgery, but the impact on outcome
is unknown.18,23 Four new primary tumors were detected (5% of
patients) in our study, three of which were treated with curative
intent. This is a lower figure than some studies suggest,13 but
this may reflect the higher recurrence rate and overall poorer
survival in the context of locally advanced lung cancer.
At present, there is no good evidence to advocate the use
of cross-sectional imaging as a screening tool in the follow-up
of NSCLC, and this lack of data is reflected in the varying
guidelines on best follow-up practice (Table 5). Patients who
have undergone radiotherapy rarely have a normal CXR or
CT post-treatment. Although filling in of radiation-induced
bronchiectatic change on CT may be indicative of local
recurrence,27 CXR and CT cannot reliably distinguish ne-
crotic tumor or fibrous scar tissue from residual tumor, with
sensitivity and specificity for CT being 67%–77% and 85%,
respectively.28,29 In patients with previously treated lung
cancer, the sensitivity and specificity of PET for detecting
relapse range from 70% to 100% and 67% to 97%, respec-
tively, even in asymptomatic patients.30–32 In patients with
suspected relapse, CT seems poor at accurately assigning
extent of relapse when compared with PET (24% versus
86%).33 CT underestimated disease extent in 37% patients,
which is important when considering potentially curative
salvage therapy. However, increased uptake on PET can be
seen following radiotherapy for up to 6 months.30 All six
patients in our series with local thoracic recurrence had
histologic confirmation. Unfortunately, PET was not avail-
able in our institution, and we are therefore not able to
determine what impact this would have had on timing of
detection of relapse, treatment, or survival.
Sixty-four percent of our patients developed symptoms
between scheduled visits. Although from our data it appears
that several relapses were detected at routine appointments, if
patients have a scheduled appointment in the near future, they
may wait rather than presenting acutely with symptoms. This
is a potential source of bias, and the proportion of patients
developing symptoms of recurrence between visits may, in
fact, be even higher. In no case did blood biochemistry alone
detect relapse.
There are limitations to this study, namely, the small
population size, and consequently there are wide confidence
intervals for survival data. Although all patients had locally
advanced disease, they comprised a heterogeneous popula-
tion. However, we still demonstrated a significant difference
in frequency of cross-sectional imaging after controlling for
trial type and therefore also disease stage.
In summary, our results suggest that in patients with
locally advanced NSCLC, routine blood tests are noncontrib-
utory and routine frequent cross-sectional imaging does not
alter survival after definitive combined modality therapy
because few patients relapse with curable disease.
TABLE 5. Summary of Follow-up Guidelines in Locally Advanced Lung Cancer
Follow-up Recommendations
Post-Chemoradiotherapy Post-Chemoradiotherapy and Surgery
Guideline Stage Clinical Follow-up Radiologic Follow-up Clinical Follow-up Radiologic Follow-up
American College of
Radiology
Appropriateness
criteria,
200024
IIIA Every 2–4 mo for
2 yr; every 6 mo
to 5 yr; yearly
thereafter
CXR every 6 mo for 5 yr
then yearly for life.
Routine cross-sectional
imaging not
recommended until
more effective salvage
therapy is developed
Every 2–4 mo for
2 yr; every 6 mo
to 5 yr; yearly
thereafter
CXR every 6 mo for 5 yr
then yearly for life. CT
may replace CXR in
high-risk patients
American Society of
Clinical Oncology
guidelines for
unresectable
NSCLC, 20035
Nonresectable Every 3 mo for 2
yr; every 6 mo
to 5 yr; yearly
thereafter
Yearly CXR may be
reasonable to detect
2nd lung cancers.
Cross-sectional studies
should only be
performed as indicated
by the patient’s
symptoms
n/a n/a
National Institute of
Clinical Excellence
of the United
Kingdom, 200525
Advanced Every 1–2 mo for
6 mo
For 6 mo to check
for postop
complications
National
Comprehensive
Cancer network
clinical
practice guidelines,
200626
Every 4 mo for 2
yr; every 6 mo
to 5 yr; annually
thereafter
CXR as clinical follow
up. CT chest 4–6 mo
postop as baseline then
annually
CXR, chest radiograph; NSCLC, non-small cell lung cancer; n/a, not available; CT, computed tomography.
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